Literature DB >> 11458045

Long-term followup after laparoscopic nephropexy for symptomatic nephroptosis.

E Plas1, K Daha, C R Riedl, W A Hübner, H Pflüger.   

Abstract

PURPOSE: Symptomatic nephroptosis is a rare disease requiring surgical therapy only in select cases. Laparoscopic nephropexy has been reported as minimally invasive treatment for symptomatic patients. We evaluated our long-term outcome after laparoscopic fixation of the kidney with an alloplastic mesh graft.
MATERIALS AND METHODS: Since 1992, 30 patients have undergone laparoscopic transperitoneal nephropexy for symptomatic nephroptosis. All patients were preoperatively investigated by excretory urography (IVP) and split renal scan in the supine and upright positions. For fixing the kidney to the abdominal wall a polyglactin and polypropylene mesh graft was used in 6 and 24 cases, respectively. A total of 17 patients with a minimum followup of 5 years participated in an assessment of long-term outcome. Clinical examination, IVP and split renal function testing were performed with patients lying and standing. Patients were further questioned about postoperative satisfaction and whether they would undergo the procedure again.
RESULTS: Of 17 patients 10 completed all investigations, 3 were contacted by telephone and 4 were lost to followup. Median followup was 5.9 years. Improvement in symptoms was reported in all cases with complete relief in 11 and intermittent flank pain requiring no medication in 2. There were no postoperative urinary tract infections or hematuria observed with improved hypertension requiring no postoperative medication in 1 case. Postoperatively IVP showed no recurrence in 8 of 10 patients but there was 5 cm. or greater recurrent ptosis in 2. Recurrence developed after using the polyglactin and polypropylene mesh grafts. Comparing preoperative and postoperative (123)iodine renal scans revealed significant improvement in renal function in 9 cases (p <0.05). There was no postoperative difference in split renal function and only 1 patient did not improve. No complications were noted except 1 symptomatic recurrence 3 months after the initial operation that required open surgical fixation. A total of 11 patients were completely satisfied with the long-term outcome and 2 were moderately satisfied. Of the patients 12 would undergo the procedure again, including 2 with persistent slight flank pain. One patient was inconsistent in regard to whether she would undergo the procedure again.
CONCLUSIONS: Symptomatic nephroptosis is a bothersome disease requiring therapy only after thorough evaluation, including IVP and split renal scan with patients supine and upright. The good clinical outcome and highly satisfactory cosmetic result support laparoscopic nephropexy as the treatment of choice. Short-term and long-term results prove the efficacy of renal fixation with alloplastic mesh graft as minimally invasive therapy with a high success rate.

Entities:  

Mesh:

Year:  2001        PMID: 11458045

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

1.  Position-related renal perfusion disturbances as a possible underestimated mechanism in patients with resistant hypertension: a case vignette.

Authors:  Jan Schiefer; Holger Amthauer; Philipp Genseke; Peter R Mertens; Christos Chatzikyrkou
Journal:  Int Urol Nephrol       Date:  2017-07-11       Impact factor: 2.370

Review 2.  A comprehensive radiologic review of abdominal and pelvic torsions.

Authors:  Richard Bonney; Jonathan W Revels; Sherry S Wang; Rick Lussier; Courtney B Dey; Douglas S Katz; Mariam Moshiri
Journal:  Abdom Radiol (NY)       Date:  2021-01-02

3.  Renal scintigraphy in diagnosis and management of nephroptosis.

Authors:  Santhi Bhushan Murari; Tejonath Gadepalli; Vvs Prabhakar Rao; Rapur Ram
Journal:  Indian J Nucl Med       Date:  2012-01

4.  Pediatric robotic assisted laparoscopic nephropexy: case study.

Authors:  Danesh Bansal; W Robert Defoor; Paul H Noh
Journal:  Springerplus       Date:  2013-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.